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nhanced External
ounterpulsation
hat Can We Learn From
he Treatment of Neurasthenia?*
tephen S. Gottlieb, MD,†
leana L. Piña, MD‡
altimore, Maryland; and Cleveland, Ohio
eurasthenia is defined by the Columbia Encyclopedia as
a condition characterized by general lassitude, irritability,
ack of concentration, worry, and hypochondria.” The term
as introduced into psychiatry in 1869 by G. M. Beard, an
merican neurologist. Used by Freud to describe a “funda-
ental disorder in mental functioning,” the term was
pplied to people with a large constellation of symptoms and
s now rarely used.
See page 1198
In 1910, when neurasthenia was considered an actual
isorder, Howard Kelly from Johns Hopkins University
ublished a series on 78 patients with neurasthenia who
ere treated for mobile kidneys (1). Mobile right kidney
nephroptosis) was said to be found in one-fourth of all
omen and to be the cause of discomfort or pain in many.
ymptoms of a moveable kidney could be confirmed by
nducing pain by hydrodistention of the renal pelvis through
ureteral catheter. The appropriate treatment was surgery
o suspend the kidney in place (nephropexy). Although Dr.
elly acknowledged that mobile kidneys were not the cause
f all neurasthenia, his findings suggested major benefit of
urgery for those women with neurasthenia. Local symp-
oms of nephroptosis were relieved in most patients, and “in
surprisingly large number of cases the neurasthenic symp-
oms also disappear[ed].” Of the worst cases, 60% were
elieved of both “pain in the side and the nervousness.” Case
eports provided examples of increased weight, elimination
f chronic headaches, and resolution of cough after surgery.
In 2006, Feldman et al. (2) provide evidence that patients
ith heart failure can benefit from enhanced external
ounterpulsation (EECP). The evidence that the authors
resent is a small rise in the percentage of patients with an
ncrease in exercise time of 60 s (10% more than that
bserved in the control group). In this PEECH (Prospec-
ive Evaluation of EECP in Congestive Heart Failure) trial,
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Cardiology, University of Maryland, Baltimore, Maryland;c
nd the ‡Department of Cardiology, Case Western Reserve University, Cleveland,
hio.ubjective questionnaires also improved, but there was no
ignificant increase in peak oxygen uptake (VO2). The
uthors admit that the failure to increase peak VO2 could, in
act, mean that the increase in exercise time is due to a
lacebo effect. To counter this hypothesis, Feldman et al.
efer us to work by Metra evaluating metoprolol and
arvedilol. Metra et al. (3) showed no changes in peak VO2
n the carvedilol group, despite better cardiac performance.
t should be noted, however, that ventilatory threshold (VT)
id not change with either drug. Lack of a change in VT
mplies that true exercise capacity did not change with either
rug, because exercise duration is a poor measure of func-
ional capacity and functional capacity does not correlate
ith hemodynamics (4). Therefore, Metra’s study does not
upport the notion that the findings in PEECH demon-
trate improved exercise capacity or cardiac function with
ECP.
The beneficial effects of EECP in ischemic disease have
een attributed to diastolic augmentation of arterial pressure
ith enhanced venous return to the heart. The extracardiac
ffects of EECP, however, are less well studied. Additional
ossible targets for EECP in heart failure would include
levated peripheral vascular resistance and endothelial dys-
unction. One could speculate that the “training effects” of
epetitive inflations and deflations of compressive cuffs with
hear stress could improve peripheral resistance and enhance
ndothelial function similar to that of exercise training (5,6).
hould a “training effect” be occurring with peripheral im-
rovements in vascular resistance and endothelial function, one
hould expect a change in peak VO2 as well. The literature
eporting drops in vascular resistance and improvements in
ndothelial function have all been accompanied by substan-
ial increases in peak VO2 (7–11). Therefore, we must return
o the placebo theory once more.
The connection between the neurasthenia and the
EECH reports published almost a century apart should be
he realization that improvement after an intervention
ight be caused by the belief that the treatment will work;
he mechanisms by which an aggressive intervention can
ause benefit are manifold.
We usually think of the placebo effect as a subjective
esponse to an inert ingredient. When evaluating interven-
ions, however, the response to a placebo or a medically
nefficacious intervention might depend upon true physio-
ogic changes. For example, placebo-induced activation of
-opioid receptor-mediated neurotransmission has been
emonstrated and could lead to the pain relief seen with
lacebos or acupuncture (12).
Frequent patient visits (the EECP protocol led to pa-
ients being seen daily for 7 weeks) might not only improve
ttitude and psychological status but might have more
angible benefits as well. The ability to adjust medications or
ddress problems early could promote improved medical
are—the state of enhanced surveillance.
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September 15, 2006:1206–7 Editorial CommentDevice trials are particularly susceptible to improvement
n symptoms unrelated to the direct effects of the interven-
ion. It is difficult to design a study to prove that devices
xert more of an effect than ordinary placebos, but there are
ublications which suggest the more aggressive an interven-
ion, the greater the response (13,14). Supporting this
ypothesis are the findings that intravenous placebo is more
ffective for hypertension than a pill (15). Similarly, sham
urgery seems to markedly decrease angina; in an investiga-
ion of the effects of internal mammary artery ligation, 80%
f both the active and the sham groups responded (16).
Many studies show increased exercise time when patients
ith heart failure perform stress tests while receiving pla-
ebo. However, it has also been demonstrated that those
eceiving placebo increase exercise time more than a control
roup receiving no intervention. In one study, placebo
herapy resulted in a mean 81-s improvement in exercise
uration. This was statistically significant when compared
ith pretreatment baseline and to the duration achieved in
he non-placebo control group (17).
The authors acknowledge that a placebo effect is possible,
nd we must agree that it is often difficult to devise an
ppropriate control for a device. Patient and doctor unblind-
ng in a device study is usually easy, and ethical concerns
rohibit risky controls. Some controls even have the poten-
ial of direct positive or negative consequences. However, it
s obligatory for designers of any study to eliminate as many
on-medical effects of an intervention as possible so that the
rue medical outcome can be assessed.
In the PEECH trial, the non-medical effects of the
ntervention were not controlled. Furthermore, only slight
enefit was seen, there was a large dropout rate (which will
robably inflate the percentage of patients categorized as
esponders), and the subgroup analyses are post hoc and
ased on few patients.
In 2004, Medicare received 410,862 billing claims for
ECP for a total of over $54 million in charges (personal
ommunication by Centers for Medicare and Medicaid
ervices). Angina as an indication accounted for 94.9% of
laims with approximately 10% having been denied. Because
edicare pays for only 80% of the charges and if all denials
emained, then the cost to Medicare was $29,530,476, leaving
8,427,224 to be paid by secondary insurance or patients.
his amount is surprising in light of the newness of this
herapy for angina. With the growing number of heart
ailure patients in the U.S. and the even more important
ncrease in the Medicare population, the use of EECP in
eart failure merits a very close look. Although costs such as
hese are acceptable for therapies with proven benefits, they
re a reason for even greater scrutiny for a therapy with more
odest or perhaps placebo-attributed effects.
1Better-controlled studies are needed before we can ascribe
benefit to EECP for patients with heart failure. Only then
ould we place it in the already extensive treatment algo-
ithm for this complex syndrome.
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